Our Health Economics and Outcomes Research team provides scientific results that help our clients earn their brands’ full potential
Pharmaceutical, biotech, and medical device companies need HEOR to evaluate multiple types of financial information: costs, charges, and expenditures to assess cost-effectiveness and product value to engage their stakeholders.
HEOR TO SUPPORT PRODUCT VALUE
HEOR is a key element of market access that covers real-world data, quality of life, budget impact, and cost-effectiveness, along with clinical efficiency. Healthcare decision-makers and payers are requiring this kind of evidence to fully understand the value of their products.
We know HEOR is a vital component of medical device clinical strategy to optimise market adoption and reimbursement by leveraging data to support product differentiation and communicating real-world product value. Thus, we not only advise on the most suitable instrument in each study, we also value the psychometric properties and manage the selection and permits necessary for its completion, helping to collect the evidence needed to prove the cost-effectiveness of any given drug.
HEOR WITHIN OBSERVATIONAL STUDIES
OXON specialises in the use of health economics and outcomes research (HEOR) within observational studies, providing good analytical modelling within a commercial and clinical context.
This requires a different approach and implementation to that used in clinical trials in design, implementation, analysis and interpretation. OXON performs these studies based on the objectives and/or their design using a patient-centred approach.
Our comprehensive portfolio includes: Consultancy in health economic strategy and market access, Evaluation of interventions within observational studies: cost-effectiveness, cost-utility and cost-consequence, Economic disease burden and budget impact, Statistical modelling, direct, indirect and ‘Network’ Meta-analysis.